结直肠癌的免疫及靶向治疗研究进展  

Advances in immune and targeted therapy for colorectal cancer

作　　者：李瑞华 韩正全[1] Li Ruihua;Han Zhengquan(The first affiliated hospital of Bengbu Medical College,Bengbu,Anhui,233000,China)

机构地区：[1]蚌埠医学院第一附属医院,安徽蚌埠233000

出　　处：《齐齐哈尔医学院学报》2023年第10期979-983,共5页Journal of Qiqihar Medical University

摘　　要：结直肠癌是我国最常见的恶性肿瘤之一,早期症状不明显,诊断率低,大多数患者发现时已属于晚期。近年来,免疫和靶向治疗的兴起,使结直肠癌患者的治疗模式发生了改变,以免疫和靶向为主的联合治疗已成为晚期结直肠患者后线治疗的一种新策略,并取得了良好的效果。本篇文章就晚期/转移性结直肠癌患者的免疫和靶向治疗以及最近几年的研究现状和进展进行梳理总结。Colorectal cancer is one of the most common malignant tumors in China.Early symptoms are not obvious,the diagnosis rate is low,and most of the tumor are already in advanced stage when they were found.In recent years,the rise of immune and targeted therapies had changed the treatment paradigm for patients suffered from colorectal cancer.Combination therapy based on immunotherapy and targeted therapy has become a novel strategy for the back line treatment of patients with advanced colorectal cancer,and has been proved to obtained good results.This article compares and summarizes the immune and targeted therapies,and the current status and progress of research in recent years for patients with advanced/metastatic colorectal cancer.

关 键 词：结直肠癌 免疫治疗 靶向治疗 

分 类 号：R735.3[医药卫生—肿瘤]